



Pharma Mar group reports first half financial results

- **The group's income of 97 M€ for the first half 2017 grew 5.2% and EBITDA has also improved respectively**
- **PharmaMar has continued to improve efficiency, with operative costs being reduced by 2.3%**

Madrid, July 26th, 2017: Pharma Mar (MSE: PHM) has reported today a total income of 96.9 M€ for the first half of 2017, a 5.2% increase on the same period 2016. The total income for its oncology unit has increased 4.8% for the first six months of 2017, reaching 51.4 M€. This result is based on the sales of Yondelis®, these being 43.3 M€, plus the registered income from royalties and those from different licensing agreements. The Consumer Chemicals Division has also registered, up to June the 30th, an increase of 7.3% in sales, these reaching 42.17 M€.

For the first half of 2017, the Group's EBITDA has improved to +80,000 euros as compared to -5.6 M€ in the same period last year. This considerable improvement is due to an increase in the group's total income, plus the control of operative expenses (R&D, Marketing and Sales, Administration, and other costs), decreasing by 2.3% in the first half of 2017. This takes into account that the company is on track with the estimated calendar for each clinical trial. PharmaMar expects to announce the results of the phase III trial with Zepsyre® (PM1183) in platinum resistant ovarian cancer by the early 2018. Recruitment of patients is still underway for the phase III trial with Zepsyre® in small-cell lung cancer. The Company also expects to initiate a phase III study with Zepsyre® in BRCA 2 breast cancer in Q4 2017. PharmaMar continues to await an answer from the Committee for Medicinal Products for Human Use (CHMP) on the approval for the commercialization of Aplidin® in Europe for the treatment of multiple myeloma in Q4 of 2017.

Including the robust development program and regulatory calendar, the group has registered a net attributable loss of -7.3 M€, an improvement against 2016's first term results of -13.1 M€ for the same period.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre™ (PM1183), plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: + 34609493127
Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215
Phone: +34 918466000



Investors:

José Luis Moreno Martínez-Losa –Investor Relations & Capital Markets Director
investorrelations@pharmamar.com
Phone: +34 914444500
Or please visit our website at www.pharmamar.com

###